DZNE Cerebral Amyloid Angiopathy Study

Background and aims

Cerebral amyloid angiopathy (CAA) is a disease of the blood vessels in the brain in which proteins, known as amyloid, are deposited in the walls of the blood vessels. There are initial indications of possible mechanisms and biomarkers in the blood and cerebrospinal fluid that influence the course of the disease. However, many questions remain unanswered, which will be investigated in this study.


The DZNE is conducting this study at the sites in Bonn, Berlin, Dresden, Göttingen, Greifswald, Magdeburg, Munich, Tübingen and Ulm in cooperation with the local clinics. The study will include 300 participants who have been diagnosed with probable cerebral amyloid angiopathy (CAA).

Course of the study

The study is divided into 6 visits, each of which will be carried out at one-year intervals. All test subjects will receive clinical and neuropsychological examinations. MRI examinations and biomaterial collection are also planned.

Principle Investigator: Prof. Dr. Gabor Petzold
Start of the study: beginning of 2024
Status: multi centric, study under preparation

Study coordination / Projectmanagement

Dr. Marie Coenjaerts
+49 228 43302-856
+49 228 43302-812

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: